Home/Pipeline/ASTRO Registry

ASTRO Registry

Spinal Fusion

Post-MarketActive

Key Facts

Indication

Spinal Fusion

Phase

Post-Market

Status

Active

Company

Artoss

About Artoss

Artoss is a commercial-stage orthobiologics company with its core product, NanoBone, already approved and used in over 100,000 surgical cases in the U.S. and EU. The company's technology is centered on a unique nanocrystalline hydroxyapatite embedded in an amorphous silica gel matrix (ASG), which is rapidly replaced by the patient's own organic bone matrix. Led by a seasoned executive team with deep experience in medical device sales and orthobiologics, Artoss is targeting the large and growing bone graft substitute market by positioning NanoBone as a cost-effective, easy-to-use, and clinically effective alternative to autograft and more expensive biologics. The company is actively gathering real-world clinical data through several patient registries to further validate and expand the use of its product.

View full company profile

Therapeutic Areas

Orthopedics Trauma Spinal Surgery

Other Spinal Fusion Drugs

Drug	Company	Phase	Status
JAZBI™ Cubes	SDIP Innovations	Preclinical	Active
Expandable Interbody Portfolio	Globus Medical	Iterative Development	Active
Mimetic Metal Technology Development	CoreLink Surgical	Development/Commercial	Active
Bone Graft Substitute	BiologicsMD	Pre-clinical	Active
VisuALIF	SpineSmith	Commercial	Active
Hive Smart Implant Exploration	NanoHive Medical	Pre-clinical R&D	Active
ProLift Pivot Expandable Spacer System	Life Spine	FDA Cleared	Active
NEXXT MATRIXX Clinical Evidence Study	Nexxt Spine	Post-Market Study	Active
AGA111	Angitia Biopharmaceuticals	Phase 3	Active
X-PAC® Portfolio Expansion	Expanding Innovations	Development	Active
SOLACE™	Xenix Medical	Commercial	Active
TrellOss Porous Ti Interbody System	HighRidge Medical	Approved	Active